{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:34:06Z","timestamp":1765355646688,"version":"3.40.3"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.biologicals.2012.04.007","type":"journal-article","created":{"date-parts":[[2012,5,30]],"date-time":"2012-05-30T18:31:45Z","timestamp":1338402705000},"page":"345-352","source":"Crossref","is-referenced-by-count":13,"title":["Virus reduction in an intravenous immunoglobulin by solvent\/detergent treatment, ion-exchange chromatography and terminal low pH incubation"],"prefix":"10.1016","volume":"40","author":[{"given":"Peter L.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Dunkerley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2012.04.007_bib1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1054\/blre.2000.0129","article-title":"Reducing the risk of infection from plasma products: specific preventative strategies","volume":"14","author":"Burnouf","year":"2000","journal-title":"Blood Rev"},{"key":"10.1016\/j.biologicals.2012.04.007_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biologicals.2006.01.002","article-title":"Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins","volume":"35","author":"Kempf","year":"2007","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2012.04.007_bib3","series-title":"Intravenous immunoglobulins in clinical practice","first-page":"67","article-title":"Viral safety of IvIg","author":"Yap","year":"1997"},{"key":"10.1016\/j.biologicals.2012.04.007_bib4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1423-0410.1999.7740204.x","article-title":"Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects","volume":"77","author":"Chidwick","year":"1999","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2012.04.007_bib5","first-page":"199","article-title":"Chromatograpic removal of viruses from plasma derivatives","volume":"81","author":"Burnouf","year":"1993","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.biologicals.2012.04.007_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1423-0410.1962.tb03274.x","article-title":"Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier","volume":"7","author":"Kistler","year":"1962","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2012.04.007_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins IV A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.biologicals.2012.04.007_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/ja01170a048","article-title":"The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and B1-lipoprotein into subfractions of human plasma","volume":"71","author":"Oncley","year":"1949","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.biologicals.2012.04.007_bib9","unstructured":"Committee for Proprietary Medicinal Products for Human Use. European medicines agency: guideline on plasma-derived medicinal products. EMA\/CPMP\/BWP\/706271\/2010."},{"key":"10.1016\/j.biologicals.2012.04.007_bib10","first-page":"147","article-title":"Viral safety of solvent-detergent treated blood products","volume":"81","author":"Horowitz","year":"1993","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.biologicals.2012.04.007_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/biol.2002.0328","article-title":"Comparable virus inactivation by bovine or vegetable derived tween 80 during solvent\/detergent treatment","volume":"30","author":"Seitz","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2012.04.007_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1537-2995.1985.25686071422.x","article-title":"Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations","volume":"25","author":"Horowitz","year":"1985","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2012.04.007_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/MJT.0b013e318160c1b7","article-title":"Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview","volume":"15","author":"Soluk","year":"2008","journal-title":"Am J Ther"},{"key":"10.1016\/j.biologicals.2012.04.007_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1423-0410.2003.00279.x","article-title":"Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process","volume":"84","author":"Trejo","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.biologicals.2012.04.007_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/biol.1997.0115","article-title":"The removal of model viruses, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatographic procedures","volume":"25","author":"Cameron","year":"1997","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2012.04.007_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1470-8744.1998.tb00516.x","article-title":"Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albuman","volume":"28","author":"Adcock","year":"1998","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.biologicals.2012.04.007_bib17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/bit.22051","article-title":"Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products","volume":"102","author":"Strauss","year":"2009","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.biologicals.2012.04.007_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biologicals.2007.02.005","article-title":"Virus inactivation by protein denaturants used in affinity chromatography","volume":"35","author":"Roberts","year":"2007","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2012.04.007_bib19","first-page":"1124","article-title":"Use of sodium hydroxide for cleaning and sanitising chromatography media and systems","volume":"18","author":"Healthcare","year":"2009","journal-title":"Appl Note"},{"key":"10.1016\/j.biologicals.2012.04.007_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1045-1056(03)00037-X","article-title":"Stability of minute virus of mice against temperature and sodium hydroxide","volume":"31","author":"Boschetti","year":"2003","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2012.04.007_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jaci.2009.09.008","article-title":"Hepatitis A virus antibodies in immunoglobulin preparations","volume":"125","author":"Farcet","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.biologicals.2012.04.007_bib22","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1099\/0022-1317-66-11-2501","article-title":"Incomplete neutralization of hepatitis A virus in\u00a0vitro due to lipid-associated virions","volume":"66","author":"Lemon","year":"1985","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.biologicals.2012.04.007_bib23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1537-2995.2010.03003.x","article-title":"Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from plasma protein therapeutics association member companies","volume":"51","author":"Dichtelmuller","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2012.04.007_bib24","unstructured":"European Medicines Agency. Quality risk management (ICH Q9) EMA\/INS\/GMP\/79766\/2011."},{"key":"10.1016\/j.biologicals.2012.04.007_bib25","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2249.2010.04247.x","article-title":"Efficacy and safety of a new immunoglobulin G product, Gammaplex\u00ae, in primary immunodeficiency disease","volume":"162","author":"Moy","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.biologicals.2012.04.007_bib26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1423-0410.2007.01016.x","article-title":"A\u00a0new liquid immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity","volume":"94","author":"Poelsler","year":"2008","journal-title":"Vox Sang"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510561200070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104510561200070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T02:30:57Z","timestamp":1743215457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104510561200070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S104510561200070X"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2012.04.007","relation":{},"ISSN":["1045-1056"],"issn-type":[{"type":"print","value":"1045-1056"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}